World Library  
Flag as Inappropriate
Email this Article

Xylometazoline

Article Id: WHEBN0000254302
Reproduction Date:

Title: Xylometazoline  
Author: World Heritage Encyclopedia
Language: English
Subject: Alpha-2 adrenergic receptor, Tetrahydrozoline, Corbadrine, Alpha-1 adrenergic receptor, Phenylephrine
Collection: Alpha-Adrenergic Agonists, Imidazolines, Topical Decongestants
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Xylometazoline

Xylometazoline
Systematic (IUPAC) name
2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-
4,5-dihydro-1H-imidazole
Clinical data
Trade names Otrivin
AHFS/Drugs.com
Pregnancy
category
  • C
Legal status
  • OTC
Dependence
liability
Moderate
Routes of
administration
Intranasal spray or drops, oral (capsules)
Pharmacokinetic data
Biological half-life >10 seconds
Excretion Urinary
Identifiers
CAS Registry Number  N
ATC code R01 S01
PubChem CID:
IUPHAR/BPS
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEMBL  Y
Chemical data
Formula C16H24N2
Molecular mass 244.37516 g/mol
 N   

Xylometazoline (Pronunciation: Zylow-met-TAH-zoleen), also known as xylomethazoline, is a drug which is used as a topical nasal decongestant.[1] It is applied directly into the nose, either as a spray or as drops.

Xylometazoline is marketed under many brand names (see below) but the most common by far is Otrivine. The standard adult solution strength is 0.1% w/v xylometazoline, and the dose for children under 12 is usually 0.05%. [2]

It should not be used for too long a period of time, or health system.[3]

Contents

  • Mechanism of action 1
  • Brand names 2
  • See also 3
  • References 4

Mechanism of action

The drug works by constricting the blood vessels in the nose. The decongestant effect is due to constriction of large veins in the nose which swell up during the inflammation of any infection or allergy of the nose. The smaller arteries are also constricted and this causes the colour of the nasal epithelium to be visibly paler after dosage.

Xylometazoline is an imidazole derivative which is designed to mimic the molecular shape of adrenaline. It binds to alpha-adrenergic receptors in the nasal mucosa.[4] Due to its sympathomimetic effects, it should not be used by people with high blood pressure, or other heart problems.

Extended usage of xylometazoline can result in decreased effectiveness or a buildup of tolerance against the drug.[5] The number of receptors decreases, and when the administration of the drug is ceased, chronic congestion can occur; this is called rhinitis medicamentosa, commonly referred to as rebound congestion. Moreover long-term overdosing can cause degenerative changes in nasal mucous membranes that pose another health problem.

Brand names

Xylometazoline is sold under a number of brand names worldwide, including: Antazol (Square, BD), Xylomet (Opsonin, BD) Cirovin, Klarigen (in Denmark), Nasolin, Neo-Rinoleina, Novorin, Olynth, Otrinoz, Otriven, Otrivin, Otrivine, Otrix, Rhinoset, Nosikind (in India), Naphthyzinium, Xymelyn (in Latvia), Sinutab Nasal Spray, Snup akut, Sudafed, Xylo-COMOD, Xylolin (in UAE), Xylovit, Olynth (in Serbia), Xynosine (in Pakistan, Afghanistan, Kyrgyzstan and Kazakhstan), Xymelin, Zymelin, Xylostar, Xylorin (in Poland), Kompendium (Switzerland), and Decozal (in Jordan).

See also

References

  1. ^ Eccles, R.; Eriksson, M.; Garreffa, S.; Chen, S. (2008). "The nasal decongestant effect of xylometazoline in the common cold". American journal of rhinology 22 (5): 491–496.  
  2. ^ http://www.drugs.com/mtm/xylometazoline-nasal.html
  3. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  4. ^ Haenisch, B.; Walstab, J.; Herberhold, S.; Bootz, F.; Tschaikin, M.; Ramseger, R.; Bönisch, H. (2009). "Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline". Fundamental & clinical pharmacology 24 (6): 729–739.  
  5. ^ Gold Standard Clinical Pharmacology
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.